Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)

6 Months Ended

Jun. 30, 2021

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Liabilities at Fair Value

The following table presents the changes in the development derivative liability for the three and six months ended June 30, 2021:

	Three Months Ended June 30, 2021		Six Months Ended June 30, 2021
Fair value at beginning of period	$	4,597	$	—
Non-cash research and development expense	3,547		5,795
Cash receipts from SFJ	750		1,500
Change in the fair value of development derivative liability	2,713		4,312
Fair value at end of period	$	11,607	$	11,607